Repare Therapeutics Inc
RPTX2.650USD
0.0000.00%
收盤 02/09, 16:00（美東）報價延遲15分鐘
113.91M總市值
虧損本益比TTM
關於 Repare Therapeutics Inc 公司
Repare Therapeutics Inc. is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its pipeline includes RP-3467, a Phase 1 Polo ATPase inhibitor; RP-1664, a Phase 1 PLK4 inhibitor, and lunresertib, a PKMYT1 inhibitor.
Repare Therapeutics Inc簡介
公司代碼RPTX
公司名稱Repare Therapeutics Inc
上市日期Jun 19, 2020
CEOForte (Steve)
員工數量129
證券類型Ordinary Share
年結日Jun 19
公司地址7210 Frederick-Banting, Suite 100
城市ST-LAURENT
上市交易所NASDAQ OMX - NASDAQ BASIC
國家Canada
郵編H4S 2A1
電話18574127018
網址https://www.reparerx.com/
公司代碼RPTX
上市日期Jun 19, 2020
CEOForte (Steve)
Repare Therapeutics Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Michael Zinda, Ph.D.
Dr. Michael Zinda, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
48.78K
--
Mr. Steve Forte
Mr. Steve Forte
President, Chief Executive Officer, Chief Financial Officer, Director
President, Chief Executive Officer, Chief Financial Officer, Director
25.28K
--
Ms. Sandra Alves
Ms. Sandra Alves
Senior Vice President, Chief Accounting Officer
Senior Vice President, Chief Accounting Officer
12.82K
-18800.00%
Ms. Carol Anne Schafer
Ms. Carol Anne Schafer
Independent Director
Independent Director
--
-8000.00%
Dr. David P. Bonita, M.D.
Dr. David P. Bonita, M.D.
Independent Director
Independent Director
--
--
Dr. Samarth Kulkarni, Ph.D.
Dr. Samarth Kulkarni, Ph.D.
Independent Director
Independent Director
--
--
Ms. Ann D. Rhoads
Ms. Ann D. Rhoads
Independent Director
Independent Director
--
-4000.00%
Mr. Thomas Civik
Mr. Thomas Civik
Independent Chairman of the Board
Independent Chairman of the Board
--
-7500.00%
Dr. Susan M. Molineaux, Ph.D.
Dr. Susan M. Molineaux, Ph.D.
Independent Director
Independent Director
--
--
Dr. Steven H. Stein, M.D.
Dr. Steven H. Stein, M.D.
Independent Director
Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Dr. Michael Zinda, Ph.D.
Dr. Michael Zinda, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
48.78K
--
Mr. Steve Forte
Mr. Steve Forte
President, Chief Executive Officer, Chief Financial Officer, Director
President, Chief Executive Officer, Chief Financial Officer, Director
25.28K
--
Ms. Sandra Alves
Ms. Sandra Alves
Senior Vice President, Chief Accounting Officer
Senior Vice President, Chief Accounting Officer
12.82K
-18800.00%
Ms. Carol Anne Schafer
Ms. Carol Anne Schafer
Independent Director
Independent Director
--
-8000.00%
Dr. David P. Bonita, M.D.
Dr. David P. Bonita, M.D.
Independent Director
Independent Director
--
--
Dr. Samarth Kulkarni, Ph.D.
Dr. Samarth Kulkarni, Ph.D.
Independent Director
Independent Director
--
--
收入明細
單位: USD更新時間: 1月6日 週二
單位: USD更新時間: 1月6日 週二
FY2025Q3
由於公司未披露，未能獲取相關數據
地區USD
名稱
營收
佔比
Switzerland
11.62M
0.00%
United States
0.00
0.00%
業務
地區
由於公司未披露，未能獲取相關數據
股東統計
更新時間: 2月1日 週日
更新時間: 2月1日 週日
持股股東
股東類型
持股股東
持股股東
佔比
Blue Owl Capital Holdings LP
7.82%
OrbiMed Advisors, LLC
7.42%
Shay Capital LLC
6.66%
Redmile Group, LLC
3.68%
MPM Capital Inc.
2.60%
其他
71.82%
持股股東
持股股東
佔比
Blue Owl Capital Holdings LP
7.82%
OrbiMed Advisors, LLC
7.42%
Shay Capital LLC
6.66%
Redmile Group, LLC
3.68%
MPM Capital Inc.
2.60%
其他
71.82%
股東類型
持股股東
佔比
Hedge Fund
12.13%
Investment Advisor/Hedge Fund
11.03%
Investment Advisor
8.95%
Private Equity
7.51%
Individual Investor
0.31%
Venture Capital
0.31%
Research Firm
0.17%
Family Office
0.09%
其他
59.51%
機構持股
更新時間: 1月1日 週四
更新時間: 1月1日 週四
報告期間
機構數
持股數
持股佔比
持股變動
2025Q4
116
24.72M
57.35%
-9.60M
2025Q3
151
27.75M
64.60%
-9.51M
2025Q2
171
30.95M
72.17%
-10.10M
2025Q1
185
33.16M
77.30%
-8.74M
2024Q4
193
34.29M
80.67%
-8.93M
2024Q3
196
36.17M
85.09%
-7.71M
2024Q2
200
37.54M
88.44%
-7.90M
2024Q1
203
39.40M
93.34%
-5.92M
2023Q4
206
40.21M
95.29%
-816.82K
2023Q3
207
37.21M
88.27%
-2.03M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Blue Owl Capital Holdings LP
3.37M
7.82%
-71.16K
-2.07%
Nov 21, 2025
OrbiMed Advisors, LLC
3.20M
7.42%
-124.40K
-3.74%
Nov 21, 2025
Redmile Group, LLC
1.59M
3.68%
--
--
Sep 30, 2025
MPM Capital Inc.
1.12M
2.6%
--
--
Sep 30, 2025
MPM BioImpact LLC
819.92K
1.9%
--
--
Sep 30, 2025
Renaissance Technologies LLC
724.16K
1.68%
+201.30K
+38.50%
Sep 30, 2025
Citadel Advisors LLC
699.30K
1.62%
-238.19K
-25.41%
Sep 30, 2025
Rangeley Capital LLC
645.88K
1.5%
+290.58K
+81.79%
Sep 30, 2025
Acadian Asset Management LLC
568.30K
1.32%
-112.88K
-16.57%
Sep 30, 2025
查看更多
持股ETF
更新時間: 12月6日 週六
更新時間: 12月6日 週六
機構名稱
佔比
ARK Genomic Revolution ETF
0%
Avantis US Small Cap Equity ETF
0%
Avantis US Equity ETF
0%
SPDR S&P International Small Cap ETF
0%
ARK Genomic Revolution ETF
佔比0%
Avantis US Small Cap Equity ETF
佔比0%
Avantis US Equity ETF
佔比0%
SPDR S&P International Small Cap ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
除權除息日
類型
比率
暫無數據
公告日期
除權除息日
類型
比率
暫無數據
